38. Stevens-Johnson syndrome Clinical trials / Disease details

Clinical trials : 17 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 15 - Drug target pathways : 101

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	March 15, 2023	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States
2	NCT01488396 (ClinicalTrials.gov)	February 2007	8/11/2010	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye	Stevens-Johnson Syndrome	Drug: 0.05%cyclosporin eye drop	Mahidol University	NULL	Completed	18 Years	N/A	Both	31	Phase 4	Thailand